Chemical odor from house demolition shuts down Hawaii school

| May 17, 2017

article image
Kahala Elementary School students and faculty were instructed to shelter in place in climate-controlled classrooms while fire crews investigated, Honolulu Fire Capt. David Jenkins said. School officials then called parents to pick up their children.

Spotlight

Moderna Therapeutics

Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, Elpidera, focused on rare diseases, and Caperna, focused on personalized cancer vaccines. Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals and Merck.

OTHER ARTICLES

Energy portfolio restructuring: Charting the future

Article | June 17, 2021

Consumer needs and preferences in the energy industry are evolving. Environmental, social and governance (ESG) concerns are becoming more acute—inspiring action and shifting value towards low-carbon solutions. These trends accelerated in 2020 and for the first time, market capitalization of leading low-carbon solutions companies began to overtake those of oil and gas (O&G) majors. This is despite the majors laying out energy transition strategies, setting low carbon energy targets and generating higher revenues by an order of magnitude.1 In response to this radically changing landscape, energy companies are charting divergent courses for their futures. Some continue to bet on their ability to generate returns from the O&G value chain. They are focusing on growing margins and lowering carbon intensity. Others are supplementing their capabilities with low-carbon energy solutions or exiting hydrocarbons altogether. This blog focuses on the path forward for the energy majors in Europe who are betting big on diversification.

Read More

How Is the SCIP Database Different From the REACH Regulation

Article | February 14, 2020

Companies operating in the European Union (EU) must submit data when introducing articles containing Substances of Very High Concern (SVHCs) above the 0.1 percent weight by weight (w/w) threshold. The reporting trigger for an in-scope article is currently derived from the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation’s Candidate List of SVHCs, but the data requirements for the SCIP database, triggered by the EU Waste Framework Directive (WFD), vary widely from those required by the REACH Regulation.

Read More

Euric unveils Waste & chemicals brochure

Article | February 11, 2020

Recyclers have developed state-of-art separation techniques to safely treat a wide diversity of waste streams and recover valuable materials, hence directly contributing to the circular economy. The Brochure published by Euric on ‘Sound Management of Waste & Chemicals Requirements’ highlights the main issues derived from the lack of interface between chemicals, product and waste legislation, and identifies simple solutions to boost the transition towards a more circular economy. Christer Forsgren, Chair of the Euric’s Waste & Chemicals Task Force, Environmental & Technical Director at Stena Metall AB (Sweden), and Adjunct Professor in Industrial Material Recycling at Chalmers Technical University in Gothenburg, emphasized the key role that Europe’s recycling industry plays by reducing Europe’s dependency on primary materials and by saving massive amounts of CO2 and energy.

Read More

COVID-19’S IMPACT ON CHEMICAL SUPPLY CHAINS

Article | April 8, 2020

The global COVID-19 pandemic has resulted in significant impact on chemical supply chains. Here we take a look at some of the chemicals that have been affected: Sanitization products such as Isopropyl Alcohol have experienced skyrocketing demand. Unfortunately, manufacturers are simultaneously dealing with problems that are preventing them from supplying at full capacity. While two US producers are experiencing production issues, another is having trouble with raw material Acetone supply. A fourth US producer is scheduled to restart production of IPA, but this material will take a few weeks to come online. Meeting this unprecedented demand is proving to be a challenge, and prices have increased sharply.

Read More

Spotlight

Moderna Therapeutics

Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, Elpidera, focused on rare diseases, and Caperna, focused on personalized cancer vaccines. Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals and Merck.

Events